Nkarta, Inc._
Stock Overview
About
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Company Details
Frequently Asked Questions
What does Nkarta, Inc. do?
Nkarta, Inc. is a company in the biotechnology industry industry. Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is
When was Nkarta, Inc. founded?
Nkarta, Inc. was founded in , making it 11 years old.
Where is Nkarta, Inc. headquartered?
Nkarta, Inc. is headquartered in South San Francisco, CA, United States.
How many employees does Nkarta, Inc. have?
Nkarta, Inc. employs approximately 105 people worldwide.
Is Nkarta, Inc. publicly traded?
Yes, Nkarta, Inc. is a publicly traded company with the stock ticker symbol NKTX.
